Scancell (LON:SCLP) Stock Price Crosses Below 200 Day Moving Average – Here’s What Happened

Shares of Scancell Holdings plc (LON:SCLP) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 9.91 and traded as low as GBX 9.85. Scancell shares last traded at GBX 10.05, with a volume of 461,593 shares.

Scancell Trading Up 1.9%

The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company’s 50 day moving average is GBX 9.63 and its 200 day moving average is GBX 9.91. The stock has a market capitalization of £105.23 million, a price-to-earnings ratio of -8.05 and a beta of 0.35.

Scancell (LON:SCLP) last posted its quarterly earnings results on Thursday, September 11th. The company reported GBX (1.26) earnings per share (EPS) for the quarter. On average, research analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

Insider Transactions at Scancell

In other news, insider Martin Diggle acquired 3,150,000 shares of Scancell stock in a transaction on Friday, September 12th. The stock was bought at an average price of GBX 9 per share, for a total transaction of £283,500. 15.45% of the stock is owned by corporate insiders.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma.